Started in 2008, Crawfish for Cancer (CFC Inc.) is dedicated to fundraising for multiple myeloma cancer research. By hosting events that cater to young professionals we are able to provide much needed funds in the fight against this currently incurable disease.
The passion for this cause is a result of the founder of CFC, Inc.’s father having had multiple myeloma. Lieutenant Colonel Lorenzo Mayo Crowell, USAF, Retired passed away as a result of multiple myeloma in March 2014.
The origins of CFC, Inc.’s signature event, the annual Crawfish Boil, began as a tradition at Williams College. The Founders and Board of Directors of CFC, Inc. are Williams alumni and have brought the Crawfish Boil that they started at Williams to New York City and the rest of country.
The Crawfish Boil at Williams began as a cultural event in the mind of some of the Southerners at Williams. CFC, Inc. has realized the popularity of the event among Yankees and decided to harness that popularity for a great cause, cancer research.
Our Origin Story
Multiple myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow. Plasma cells normally make proteins called antibodies to help you fight infections. In multiple myeloma cancer, a group of abnormal plasma cells (myeloma cells) multiplies, raising the number of plasma cells to a higher than normal level. Since these cells normally make proteins, the level of abnormal proteins in your blood also may go up. Health problems caused by multiple myeloma can affect your bones, immune system, kidneys and red blood cell count
We at CFC, Inc. aren’t qualified to do cancer research; therefore we turn over the success of our efforts to those that are qualified. Since 2009, our success has benefited the Multiple Myeloma Research Foundation, donating $400,000 to the MMRF as of 2016.
Started by a multiple myeloma patient, the MMRF relentlessly pursues innovative means that accelerate the development of next-generation cancer treatments to extend the lives of patients and lead to a cure.
As an end-to-end solution to accelerate drug development, they do everything they can to make sure the next generation of treatments is brought to patients as quickly as possible – from bridging drug discovery gaps through their innovative research portfolio and funding early-stage research, to developing novel business solutions that inject speed and efficiency into every step along the drug development pathway. Their model works, and they have the track-record to prove it.